Ethical and social implications of the introduction of the vaccine against the human papilloma virus in Mexico: Reflections on a proposed intervention;Implicaciones éticas y sociales de la introducción de la vacuna contra el virus del papiloma humano en México: Reflexiones sobre una propuesta de intervención

Acta Bioethica

Volumn 14, Issue 2, 2008, Pages 157-165

  de la Rosa, Alejandra Prieto ^a   Gutiérrez Delgado, Cristina ^a   Feinholz Klip, Dafna ^a   Morales González, Gisela ^a   Witlen, Renee ^b  

^a SECRETARÍA DE SALUD   (Mexico)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cervical cancer; Decision making; Ethics; HPV vaccine

Indexed keywords

EID: 61349174047     PISSN: 07175906     EISSN: 1726569X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Senado de la República de México. LX Legislatura. Gaceta Parlamentaria 2007; 126.
2. Cámara de Diputados de México. LX Legislatura. Anexos Presupuesto de Egresos 2008. Gaceta Parlamentaria 2007; 10(2.381).
3. Gutiérrez-Delgado C, Báez-Mendoza C, González-Pier E, et al. Costo-efectividad generalizado de intervenciones preventivas contra el cáncer cervical en mujeres mexicanas: Resultados de un modelo markoviano con la perspectiva del sector público. Salud Pública México 2008, 50: 2.
4. Daniels N, Sabin JE. Setting limits fairly: Can we learn to share medical resources? Oxford: Oxford University Press; 2002.
5. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356(19): 1915-1927.
6. Baden LR, Curfman GD, Morrissey S, Drazen JM. Human papillomavirus vaccine. Opportunity and challenge. N Engl J Med 2007; 356:1990-1991.
7. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. The Lancet 2007; 369: 2161-2170.
8. Agosti JM, Goldie SJ. Introducing HPV Vaccine in Developing Countries. Key Challenges and Issues. N Engl J Med 2007; 356(19): 1908-1910.
9. Danish Center for Health Technology Assessment. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV). A health technology assessment-Summary 2007; 9(1).
10. Rambout L, Hopkins L, Button B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007; 177(5): 469-479.
11. Elbasha E, Dasbach E, Insigna R. Model for assessing Human Papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13(1): 28-41.
12. Suba EJ, Donnelly AD, Furia LM, et al. Cervical cancer prevention for all the world's women: genuine promise resides in skilled quality management rather than novel screening approaches. Diagn Cytopathol 2007; 35: 187-191.
13. Lippman A, Melnychuk R, Shimmin C, Boscoe M. Human papillomavirus, vaccines and women's health: questions and cautions, CMAJ 2007;177: 484-487.
14. Instituto Mexicano de la Juventud. Encuesta Nacional de Juventud 2005. Resultados Preliminares. México; 2005.
15. Department of Health and Ageing. Australian Government funding of Gardasil. Australian Government; 2006.
16. Consejo Nacional de Vacunación. Manual de procedimientos técnicos de vacunación. México: actualización 2003.
17. Humiston SG, Rosenthal SL. Challenges to vaccinating adolescents: vaccine implementation issues. The Ped Infect Dis J 2005; 24(6): S134-S140.
18. Franco EL. Commentary: Health inequity could increase in poor countries if universal HPV vaccination is not adopted. BMJ 2007, 335: 378-379.
19. Coughlin S. Ethical issues in epidemiologic research and public health practice. Emerging Themes in Epidemiology 2006; 3: 16.
20. Raffle AE. Challenges of implementing human papillomavirus (HPV) vaccination policy. BMJ 2007; 335: 375-377.
21. Subsecretaría de Promoción y Prevención de la Salud. NOM-014-SSA2-1994: Sobre el control y tratamiento del cáncer cérvico-uterino. México: Secretarå de Salud, Diario Oficial de la Federación, 31 de mayo de 2007.
22. World Health Organization. Preparing for the introduction of HPV Vaccines: Policy and Programme Guidance for Countries 2006. Disponible en http://www.who.int/reproductive-health/publications/ hpvvaccines/
23. Zimmerman RK. Ethical analysis of HPV vaccine policy options. Vaccine 2006; 24: 4812-4820.
24. Eggertson L. Adverse events reported for HPV vaccine, CMAJ 2007; 177(10): 1169-1170.
25. Center for Disease Control (CDC). Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices. ACIP 2007; 56(RR02);1-24.
26. De Melo-Martin I. The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection. The Oncologist 2006; 11(4): 393-396.
27. Program for Appropriate Technology in Health (PATH). Introducing HPV Vaccines in Developing Countries: Overcoming the Challenges: 2005.
28. Charo R. Politics, parents, and prophylaxis-mandating HPV vaccination in the United States. N Engl J Med 2007; 356: 1905-1908.
29. Colgrove J. The Ethics and Politics of Compulsory HPV Vaccination. N Engl J Med 2006; 355(23): 2389-2391.
30. Verweij M, Dawson A. Ethical principles for collective immunization programmes. Vaccine 2004; 22(3): 122-3126.
31. Wilson JMG, Jungner G. Principles and Practice of screening for disease. WHO Public Health Papers 1968; Ch. 2: 26-39.
32. Secretaría de Salud de México. Información para la rendición de cuentas 2001-2005. México: 2006.